相关实验视频
Updated: Sep 12, 2025

Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
与氧尿素相关的多种皮肤癌:病例报告和文献综述
Safoura Shakoei1,2, Zahra Nilfroushan2
1Department of Dermatology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
骨髓扩散性疾病的尿素 (HU) 治疗与非黑色素瘤皮肤癌 (NMSC) 的发展有关. 长期接受HU治疗的患者需要对NMSC进行警的查和预防性护理.
科学领域:
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 氧尿素 (HU) 是一种重要的抗代谢物,用于治疗骨髓增殖性疾病,如基本血小板缺血症 (ET).
- 它在治疗这些疾病方面的有效性已经得到了很好的证实.
- 然而,潜在的长期副作用需要持续调查.
研究的目的:
- 调查氧尿素 (HU) 治疗与非黑色素瘤皮肤癌 (NMSC) 之间的关联.
- 审查和总结有关HU相关皮肤癌的现有文献.
- 突出对患者管理的临床影响.
主要方法:
- 进行了全面的文献综述,分析了1991年至2022年间发表的研究.
- 在接受HU治疗的患者中评估了60例NMSC病例.
- 分析了患者人口统计数据,HU治疗持续时间,剂量和NMSC发展的延迟时间.
主要成果:
- 该研究确定了长期HU治疗和NMSC之间的显著关联.
- 状细胞癌 (SCC) 是最常见的NMSC类型,其次是行为性角质瘤 (AK),基底细胞癌 (BCC) 和恩病.
- 受影响患者的平均年龄为66.73岁,平均HU治疗持续时间为9.17年,潜伏期为7.33年.
结论:
- 医疗保健提供者必须意识到长期接受HU治疗的患者患NMSC的风险增加.
- 定期进行皮肤癌查对于接受HU治疗的患者的早期检测至关重要.
- 预防措施和及时治疗对于管理HU相关的皮肤癌至关重要.
更多相关视频
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
相关概念视频
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers